KELLY FOREIT: Open Payments
NPI 1992569107 · KOKOMO, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$646 in 41 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $288 · 2025 $646
Food & beverage: $646
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $179 |
| Novo Nordisk Inc | 14 | $145 |
| Lilly USA, LLC | 8 | $126 |
| ABBVIE INC. | 3 | $50 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $18 |
| Abbott Laboratories | 1 | $17 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 2 | $15 |
Products named: MOUNJARO, AIRSUPRA, Ozempic, FARXIGA, UBRELVY, Wegovy, Auvelity, REXULTI.
Industry payments across IN — which companies pay providers there.
